A61K 2239/59
Reproductive system
Official title: Reproductive system, e.g. uterus, ovaries, cervix or testes
A61K2239/59 (Reproductive system) appears on 193 US grants and 503 published applications in this corpus.
Search patents in A61K- Granted patents
- 193
- Published applications
- 503
- Assignees
- 272
- Inventors
- 987
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 5 |
| 2003 | 1 | 2 |
| 2004 | 1 | 3 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 2 |
| 2009 | 1 | 3 |
| 2010 | 2 | 5 |
| 2011 | 2 | 3 |
| 2012 | 0 | 4 |
| 2013 | 0 | 2 |
| 2014 | 0 | 8 |
| 2015 | 5 | 12 |
| 2016 | 4 | 10 |
| 2017 | 9 | 17 |
| 2018 | 13 | 20 |
| 2019 | 7 | 30 |
| 2020 | 14 | 42 |
| 2021 | 14 | 51 |
| 2022 | 18 | 54 |
| 2023 | 19 | 49 |
| 2024 | 30 | 63 |
| 2025 | 35 | 69 |
| 2026 | 18 | 44 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Anti-MUC1-C antibodies and CAR-T structures15 Sep 2026US 12,735,503 B2TeneoBio, Inc.
- Dendritic cell vaccination sequential to chemotherapy18 Aug 2026US 12,708,644 B2Excoso a.s.
- Fusion constructs and methods of using thereof11 Aug 2026US 12,703,747 B2Precigen, Inc.
- Treatment with tumor infiltrating lymphocyte therapies in combination with CTLA-4 and PD-1 inhibitors14 Jul 2026US 12,678,499 B2Iovance Biotherapeutics, Inc.
- Tethered interleukin-15 and interleukin-2117 Sep 2026US 2026/0274917 A1The United States of America, as represented by the Secretary, Department of Health and Human Servi
- Anti-btn3a antibodies and their use in treating cancer or infectious disorders20 Aug 2026US 2026/0242480 A1Centre National de la Recherche Scientifique (CNRS)
- Anti-btn3a antibodies and their use in treating cancer or infectious disorders20 Aug 2026US 2026/0242483 A1Centre National de la Recherche Scientifique (CNRS)
- Combinations of dendritic cell-based vaccines and checkpoint inhibitors13 Aug 2026US 2026/0232776 A1Mayo Foundation for Medical Education and Research
- Recombinant immune cell-based cell therapeutic agent for treating cancer via polyclonal expansion of tumor-infiltrating t cell in tumor6 Aug 2026US 2026/0224615 A1Korea Advanced Institute of Science and Technology
Most cited
By later US patents
- T cell receptor-deficient T cell compositions79US 9,181,527 B2Trustees of Dartmouth College · 2015
- Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting52US 9,272,002 B2The Trustees of the University of Pennsylvania · 2016
- Compositions and methods for treating cancer51US 9,402,865 B2The Trustees of the University of Pennsylvania · 2016
- Method of producing T cell receptor-deficient T cells expressing a chimeric receptor44US 9,273,283 B2Trustees of Dartmouth College · 2016
- Activated dual specificity lymphocytes and their methods of use32US 7,723,111 B2The United States of America as represented by the Department of Health and Human Services · 2010